Actions for Commissioning Teams

ACT 5 - Pain Management
This report contains data analysis looking at prescribing in Feb-12 to Jan-13.

NHS Example CCG
This report has been designed to be used in conjunction with a suite of materials including a presentation, summary sheet and toolkit focusing on the issues arising. All of the components relating to this ACT package are available to download from our website http://www.keele.ac.uk/pharmacy/general/pctsla/. Please e-mail medman@keele.ac.uk if you require log-on details.
Figure 1: Prescribing of Analgesics (BNF 4.7) by Volume (Items) and Spend (NIC) in NHS Example CCG, for the period Jan-08 to Dec-12

Figure 2: Prescribing of Analgesics (BNF 4.7) in CCGs in the West Midlands, for the period Feb-12 to Jan-13

Data: NHS BSA
Figure 3: Prescribing of Paracetamol and Paracetamol Combinations (part of BNF 4.7.1) by Volume (Items) in NHS Example CCG, for the period Jan-08 to Dec-12

Figure 4: Prescribing of Paracetamol and Paracetamol Combinations (part of BNF 4.7.1) by Volume (Items) in CCGs in the West Midlands, for the period Feb-12 to Jan-13

Data: NHS BSA
Figure 5: Prescribing of Paracetamol and Paracetamol Combinations (part of BNF 4.7.1) by Spend (NIC) in NHS Example CCG, for the period Jan-08 to Dec-12

Figure 6: Prescribing of Paracetamol and Paracetamol Combinations (part of 4.7.1) by Spend (NIC) in CCGs in the West Midlands, for the period Feb-12 to Jan-13

Data: NHS BSA
Figure 7: Prescribing of Opioid Analgesics* (BNF 4.7.2) by Volume (Items and DDDS) in the West Midlands, for the period Jan-03 to Dec-12

Figure 8: Prescribing of Opioid Analgesics* (BNF 4.7.2) by Volume (Items) in CCGs in the West Midlands, for the period Feb-12 to Jan-13

* where "strong opioids" are defined as buprenorphine, diamorphine, dipipanone, fentanyl, hydromorphone, meptazinol, methadone, morphine, oxycodone, papaveretum, pethidine and tapentadol

Data: NHS BSA

Keele University
Faculty of health
Department of medicines management
* where "strong opioids" are defined as buprenorphine, diamorphine, dipipanone, fentanyl, hydromorphone, meptazinol, methadone, morphine, oxycodone, papaveretum, pethidine and tapentadol

Data: NHS BSA
Table 1: West Midlands Key Performance Indicator: Increase the percentage of strong opioids prescribed as morphine to 51.10%

<table>
<thead>
<tr>
<th>CCG</th>
<th>% morphine</th>
<th>NIC per Item</th>
<th>% morphine</th>
<th>NIC per Item</th>
<th>Potential Annual Saving from moving to 51.10% morphine</th>
</tr>
</thead>
<tbody>
<tr>
<td>NHS Example CCG</td>
<td>45.23%</td>
<td>£29.02</td>
<td>45.93%</td>
<td>£29.02</td>
<td>£108,123</td>
</tr>
<tr>
<td>NHS Example CCG</td>
<td>53.22%</td>
<td>£23.17</td>
<td>56.04%</td>
<td>£20.93</td>
<td>0</td>
</tr>
<tr>
<td>NHS Example CCG</td>
<td>45.52%</td>
<td>£28.66</td>
<td>46.41%</td>
<td>£28.96</td>
<td>£42,704</td>
</tr>
<tr>
<td>NHS Example CCG</td>
<td>52.14%</td>
<td>£27.26</td>
<td>52.46%</td>
<td>£27.38</td>
<td>0</td>
</tr>
<tr>
<td>NHS Example CCG</td>
<td>54.09%</td>
<td>£26.44</td>
<td>54.25%</td>
<td>£26.94</td>
<td>0</td>
</tr>
<tr>
<td>NHS Example CCG</td>
<td>52.21%</td>
<td>£27.32</td>
<td>55.68%</td>
<td>£24.39</td>
<td>0</td>
</tr>
<tr>
<td>NHS Example CCG</td>
<td>62.74%</td>
<td>£22.12</td>
<td>63.48%</td>
<td>£24.23</td>
<td>0</td>
</tr>
<tr>
<td>Area Team 1</td>
<td>50.65%</td>
<td>£27.00</td>
<td>51.70%</td>
<td>£26.78</td>
<td>£150,827</td>
</tr>
<tr>
<td>NHS Example CCG</td>
<td>58.24%</td>
<td>£26.98</td>
<td>61.55%</td>
<td>£24.39</td>
<td>0</td>
</tr>
<tr>
<td>NHS Example CCG</td>
<td>45.70%</td>
<td>£27.28</td>
<td>45.69%</td>
<td>£24.96</td>
<td>£44,251</td>
</tr>
<tr>
<td>NHS Example CCG</td>
<td>49.12%</td>
<td>£27.62</td>
<td>47.94%</td>
<td>£27.59</td>
<td>£40,417</td>
</tr>
<tr>
<td>NHS Example CCG</td>
<td>40.61%</td>
<td>£29.30</td>
<td>42.36%</td>
<td>£27.37</td>
<td>£248,702</td>
</tr>
<tr>
<td>NHS Example CCG</td>
<td>46.82%</td>
<td>£26.75</td>
<td>48.53%</td>
<td>£25.50</td>
<td>£44,551</td>
</tr>
<tr>
<td>NHS Example CCG</td>
<td>25.70%</td>
<td>£31.43</td>
<td>24.82%</td>
<td>£30.07</td>
<td>£312,931</td>
</tr>
<tr>
<td>NHS Example CCG</td>
<td>29.52%</td>
<td>£30.76</td>
<td>28.41%</td>
<td>£30.30</td>
<td>£231,088</td>
</tr>
<tr>
<td>Area Team 2</td>
<td>41.72%</td>
<td>£28.68</td>
<td>42.12%</td>
<td>£27.28</td>
<td>£921,940</td>
</tr>
<tr>
<td>NHS Example CCG</td>
<td>51.07%</td>
<td>£20.46</td>
<td>49.84%</td>
<td>£21.17</td>
<td>£7,492</td>
</tr>
<tr>
<td>NHS Example CCG</td>
<td>35.29%</td>
<td>£26.32</td>
<td>40.04%</td>
<td>£28.56</td>
<td>£19,320</td>
</tr>
<tr>
<td>NHS Example CCG</td>
<td>45.33%</td>
<td>£25.48</td>
<td>41.31%</td>
<td>£26.93</td>
<td>£63,599</td>
</tr>
<tr>
<td>NHS Example CCG</td>
<td>37.63%</td>
<td>£31.73</td>
<td>39.32%</td>
<td>£30.38</td>
<td>£123,192</td>
</tr>
<tr>
<td>NHS Example CCG</td>
<td>36.18%</td>
<td>£30.21</td>
<td>38.01%</td>
<td>£29.30</td>
<td>£177,450</td>
</tr>
<tr>
<td>NHS Example CCG</td>
<td>31.89%</td>
<td>£28.38</td>
<td>35.34%</td>
<td>£27.65</td>
<td>£85,172</td>
</tr>
<tr>
<td>NHS Example CCG</td>
<td>51.79%</td>
<td>£28.70</td>
<td>50.38%</td>
<td>£28.59</td>
<td>£8,693</td>
</tr>
<tr>
<td>NHS Example CCG</td>
<td>43.99%</td>
<td>£24.42</td>
<td>42.23%</td>
<td>£25.01</td>
<td>£56,998</td>
</tr>
<tr>
<td>NHS Example CCG</td>
<td>46.72%</td>
<td>£26.99</td>
<td>46.51%</td>
<td>£26.71</td>
<td>£74,748</td>
</tr>
<tr>
<td>Area Team 3</td>
<td>42.98%</td>
<td>£27.51</td>
<td>43.07%</td>
<td>£27.32</td>
<td>£616,663</td>
</tr>
<tr>
<td>West Midlands</td>
<td>44.72%</td>
<td>£27.83</td>
<td>45.15%</td>
<td>£27.15</td>
<td>£1,689,430</td>
</tr>
</tbody>
</table>

Note: For the purpose of this indicator, the following drugs are classed as strong opioid analgesics (injection formulations are excluded from this indicator): Buprenorphine, Dipipanone, Fentanyl, Hydromorphone, Morphine, Oxycodone, Papaveretum, Pentazocine, Pethidine and Tapentadol

Data: NHS BSA
Figure 11: Prescribing of Selected Opioid Analgesics (BNF 4.7.2) by Volume (Items) in the West Midlands, for the period Jan-03 to Dec-12

Figure 12: Prescribing of Selected Opioid Analgesics (BNF 4.7.2) by Volume (Items) in CCGs in the West Midlands, for the period Feb-12 to Jan-13
Actions for Commissioning Teams

Pain Management

Figure 13: Prescribing of Selected Opioid Analgesics (BNF 4.7.2) by Spend (NIC) in the West Midlands, for the period Jan-03 to Dec-12

Figure 14: Prescribing of Selected Opioid Analgesics (BNF 4.7.2) by Spend (NIC) in CCGs in the West Midlands, for the period Feb-12 to Jan-13

Data: NHS BSA
Figure 15: Prescribing of Selected Opioid Analgesics (BNF 4.7.2) by Volume (Items) in practices in NHS Example CCG, for the period Feb-12 to Jan-13

Data: NHS BSA
Figure 16: Prescribing of Buprenorphine and Fentanyl Patches (part of BNF 4.7.2) by Volume (Items) in NHS Example CCG, for the period Jan-08 to Dec-12

Figure 17: Prescribing of Buprenorphine and Fentanyl Patches (part of BNF 4.7.2) by Volume (Items) in CCGs in the West Midlands, for the period Feb-12 to Jan-13

Data: NHS BSA
Figure 18: Prescribing of Buprenorphine and Fentanyl Patches (part of BNF 4.7.2) by Spend (NIC) in NHS Example CCG, for the period Jan-08 to Dec-12

Figure 19: Prescribing of Buprenorphine and Fentanyl Patches (part of BNF 4.7.2) by Spend (NIC) in CCGs in the West Midlands, for the period Feb-12 to Jan-13

Data: NHS BSA
Figure 20: Prescribing of Bupenorphine and Fentanyl Patches (part of BNF 4.7.2) by Volume (Items) in practices in NHS Example CCG, for the period Feb-12 to Jan-13

Data: NHS BSA
Figure 21: Prescribing of NSAIDs (BNF 10.1.1) by Volume (Items) in NHS Example CCG, for the period Jan-08 to Dec-12

Figure 22: Prescribing of NSAIDs (BNF 10.1.1) by Volume (Items) in CCGs in the West Midlands, for the period Feb-12 to Jan-13

Data: NHS BSA
Figure 23: Prescribing of NSAIDs (BNF 10.1.1) by Spend (NIC) in NHS Example CCG, for the period Jan-08 to Dec-12

Figure 24: Prescribing of NSAIDs (BNF 10.1.1) by Spend (NIC) in CCGs in the West Midlands, for the period Feb-12 to Jan-13

Data: NHS BSA
Figure 25: Prescribing of NSAIDs (BNF 10.1.1) by Volume (Items) in practices in NHS Example CCG, for the period Feb-12 to Jan-13

Data: NHS BSA
Figure 26: Prescribing of Ibuprofen or Naproxen vs Other NSAIDs (BNF 10.1.1) by Volume (Items) in NHS Example CCG, for the period Jan-08 to Dec-12

Figure 27: Prescribing of Ibuprofen or Naproxen vs Other NSAIDs (BNF 10.1.1) by Volume (Items) in CCGs in the West Midlands, for the period Feb-12 to Jan-13

Data: NHS BSA
Figure 28: Prescribing of Ibuprofen or Naproxen vs Other NSAIDs (BNF 10.1.1) by Volume (Items) in practices in NHS Example CCG, for the period Feb-12 to Jan-13

Data: NHS BSA
Figure 29: Prescribing of Gabapentin and Pregabalin (part of BNF 4.7.3 and 4.8.1) by Volume (Items) in NHS Example CCG, for the period Jan-08 to Dec-12

Figure 30: Prescribing of Gabapentin and Pregabalin (part of BNF 4.7.3 and 4.8.1) by Spend (NIC) in NHS Example CCG, for the period Jan-08 to Dec-12

Data: NHS BSA
Figure 31: Prescribing of Gabapentin and Pregabalin (part of BNF 4.7.3 and 4.8.1) by Volume (items) in CCGs in the West Midlands, for the period Feb-12 to Jan-13

Figure 32: Prescribing of Gabapentin and Pregabalin (part of BNF 4.7.3 and 4.8.1) by Spend (NIC) in CCGs in the West Midlands, for the period Feb-12 to Jan-13

Data: NHS BSA
Figure 33: Prescribing of Gabapentin and Pregabalin (part of BNF 4.7.3 and 4.8.1) by Volume (Items) in practices in NHS Example CCG, for the period Feb-12 to Jan-13

Data: NHS BSA
Actions for Commissioning Teams  
Pain Management

Staff Involved in the Production of this ACT:

- Dr Nicky Birks  Medicines Evaluation Specialist
- Mrs Jo Lockett  Senior Data Analyst
- Dr Jo Seager  Medicines Evaluation Pharmacist
- Mrs Hannah Pearce  Prescribing and Public Health Analyst

Reviewers:

- Dr James Bashford  Lecturer in Primary Care Research and GP, NHS Stoke-on-Trent
- Mrs Tracy Savage  Head of Medicines Management, Shropshire CCG

If you have any queries regarding this report please contact

Dr Jo Seager  
j.m.seager@keele.ac.uk  
01782 733565

Mrs Hannah Pearce  
h.l.pearce@keele.ac.uk  
01782 733572

All of the materials relating to this ACT package are available to download from our website http://www.keele.ac.uk/pharmacy/general/pctsla/. Please e-mail medman@keele.ac.uk if you require log-on details.

Other Available Resources

**Actions for Commissioning Teams** is part of a range of materials produced by the Department of Medicines Management at Keele University. You may also be interested in some of our other reports:

- A quarterly update of “Top 20” BNF Chapters, Sections and Chemicals by Spend and Volume with selected comparators and trends
- Reviews of developments in five key therapeutic areas that together account for approximately ¾ of prescribing spend
- Annual analysis of prescribing information to support QIPP

We also provide customised local analysis for individual practices or groups. Further examples are available on the “About Us” pages of our website as well as some open-access resources; for more information see our website: http://www.keele.ac.uk/pharmacy/general/pctsla/

You can also follow us on twitter @MedManKeele